ClinicalTrials.gg
Not yet recruitingNCT07647614Updated Jul 2, 2026

A Study to Evaluate the Efficacy and Safety of ENERGI-F705 Tablets for Parkinson's Disease

A Phase 2 interventional study of 60 milligrams of ENERGI-F705 Tablets and Placebo tablets in Parkinson's Disease (PD), sponsored by Energenesis Biomedical Co., Ltd.. Not yet recruiting at 2 sites in Taiwan. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-02.

Sponsored by Energenesis Biomedical Co., Ltd. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 121 studies in Parkinson Disease with a site in Taiwan — 33 open to participants now, 37 under way, 1 of them phase 3. Parkinson Disease · Taiwan.

Planned enrollment
18th of 99
105 · median 55
Started
2026
with 6 others
Phase 2
13 of 121
2 open now
Primary completion
2030-01
later than 35 of 36 live
Registered
118th of 121
by date

Among the 121 studies in Parkinson Disease with a site in Taiwan, this one is the 18th largest by planned enrollment of the 99 interventional ones that give a count, is one of 7 that started in 2026, is one of 13 in phase 2, reaches primary completion later than 35 of the 36 other live ones, and was the 118th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

33 of the 121 studies in Parkinson Disease with a site in Taiwan are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 121 studies in Parkinson Disease with a site in Taiwan, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if this study drug, ENERGI-F705 Tablets, is safe and works to treat participants who have Parkinson's disease and are currently on standard-of-care antiparkinsonian medications. The main question it aims to answer is:

Does ENERGI-F705 Tablets work to treat Parkinson's disease when used with standard-of-care treatment?

Investigators will compare the three treatment groups, high-dose ENERGI-F705 Tablets (120 milligrams twice daily), low-dose ENERGI-F705 Tablets (60 milligrams twice daily), and placebo tablets (a look-alike substance that contains no drug), to see if ENERGI-F705 Tablets work to treat Parkinson's disease.

Participants will:

  • Take the study drugs twice a day for 72 weeks in the treatment group
  • Take routine use of standard-of-care antiparkinsonian medications throughout the study
  • Visit the outpatient department at scheduled visits, ranging from Day 1 to approximately every 1 to 4 weeks thereafter, for checkups and tests
03

Conditions studied

  • Parkinson's Disease (PD)

Browse trials for

Keywords

  • Phase II
  • Randomized
  • Double blind
  • ENERGI
  • Parkinson' disease
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A subject is eligible for the study if all of the following apply:

  1. With either gender aged ≥ 40 to ≤ 75 years old at Visit 1 (Screening Visit)
  2. Has been diagnosed with idiopathic Parkinson's disease (defined by the Movement Disorder Society (MDS) Clinical Diagnostic Criteria for Parkinson's disease) for ≥ 2 years prior to or at Visit 2 (Day 1)
  3. Has a modified Hoehn and Yahr stage of 2 to 3 while assessed in the medication-off state at Visit 1 (Screening Visit)
  4. With MDS-UPDRS Part III (motor examination) score of 15 to 60 while assessed in the medication-off state at Visit 1 (Screening Visit)
  5. Without motor complications, which is defined as a score of 2 or less on the MDS-UPDRS Part IV score at Visit 1 (Screening Visit)
  6. Has received a stable standard-of-care regimen, as determined by the investigator, during the 12 weeks prior to Visit 2 (Day 1) and is currently on the following antiparkinsonian medications with an average levodopa equivalent daily dose (LEDD) of ≥ 300 mg during the same period, including:

    • Levodopa
    • Catechol-O-methyl transferase (COMT) inhibitors
    • Monoamine Oxidase-B (MAO-B) inhibitors
    • Ergot-derived dopamine receptor agonists
    • Non ergot-derived dopamine receptor agonists
    • Others with established levodopa-conversion factors
  7. Has adequate indices as follows at Visit 1 (Screening Visit):

    • Hematology: white blood cells (WBC) should be ≥ 3,000 cells/μL, count should be ≥ 80,000 per μL of blood
    • Coagulation: , international normalized ratio (INR), and activated partial thromboplastin time (APTT), all of which should be ≤ 1.5 times the (ULN)
    • Liver function: serum total should be ≤ 1.5 times ULN, and (AST) and alanine aminotransferase (ALT) should be ≤ 3 times ULN
    • Renal function: an estimated (eGFR) should be ≥ 60 mL/min/1.73m2, calculated by the 2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation
  8. Is willing and able to comply with all required study visits and follow-ups required by this protocol
  9. Understands the study procedures and provided written (including through use of a legally authorized representative, if necessary)
  10. Is able to complete all subject-reported outcome measures

Exclusion criteria

Exclusion Criteria:

Any subject meeting any of the exclusion criteria will be excluded from study participation:

  1. Has been diagnosed with atypical Parkinson's disease or secondary parkinsonism
  2. Has any of the following neurosurgical intervention for Parkinson's disease within 2 years prior to or at Visit 2 (Day 1):

    • Deep brain stimulation
    • Pallidotomy
    • Thalamotomy
    • Other procedures that may affect motor function
  3. With (MMSE) score of \< 24 at Visit 1 (Screening Visit)
  4. With a lifetime history of significant psychiatric disorder (e.g., alcohol use disorder, drug abuse, or suicide attempt), which in the investigator's opinion, may interfere with study participation
  5. With history of or current malignancy within 2 years prior to or at Visit 2 (Day 1)
  6. With ongoing or a documented history of within 2 years prior to or at Visit 2 (Day 1) of acute diseases or severe medical conditions, including:

    • Cardiovascular (myocardial infarction, congestive heart failure, Grade III or IV)
    • Pulmonary (severe , pulmonary hypertension, or other respiratory conditions)
    • Current severe infections, medical history, physical examination findings, or laboratory examination abnormality that in the investigators' opinion are not in stable condition and participating in the study could interfere with the results of the trial or adversely affect the safety of the subject
  7. Administered dopamine-blocking agents within 12 weeks prior to or at Visit 2 (Day 1), including:

    • Typical antipsychotics (e.g., Haloperidol, Chlorpromazine)
    • Atypical antipsychotics (e.g., Risperidone, Quetiapine or Clozapine)
  8. With clinically significant gastrointestinal disorders that may affect oral drug absorption or tolerability (e.g., inflammatory bowel disease within 12 weeks prior to or at Visit 2 (Day 1) or relevant gastrointestinal surgery recorded on a lifetime basis)
  9. With a history of gout or urolithiasis, or treatment with medications for gout or urolithiasis, within 2 years prior to or at Visit 2 (Day 1)
  10. With known to any component of the product
  11. Has participated in another clinical trial involving an investigational product, medical device, or surgical procedure within 4 weeks prior to Visit 1 (Screening Visit)

    * Note: Subjects enrolled in non-interventional clinical trials will be eligible.

  12. Female subject with who is lactating or has positive serum or urine pregnancy test at Visit 2 (Day 1)

    * Note: Female subjects with any of following conditions are considered not with childbearing potential

    • With menopause ≥ 1 year
    • Prior surgical procedures resulting in infertility
    • Documented follicle-stimulating hormone or luteinizing hormone levels consistent with status
  13. Female subjects with childbearing potential or male subjects with partners of childbearing potential who refuse to use highly effective from signing until the end of study (EOS) or early termination (ET) visit

    * Note: At least two forms of birth control must be adopted and one of which must be a barrier method. Acceptable forms include:

    • Established use of oral, injected or implanted hormonal methods of contraception
    • Placement of an intrauterine device (IUD) or intrauterine system (IUS)
    • Barrier methods of contraception: condom, or occlusive cap (diaphragm or cervical/vault caps)
  14. Is an employee of the investigator's site, the sponsor, or its delegate (e.g., contract research organization) who is directly involved in the conduct of the study
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
105 participants (estimated)

Study arms

  • Experimental
    Low-dose ENERGI-F705 Tablets

    60 milligrams of ENERGI-F705 Tablets

    Drug: 60 milligrams of ENERGI-F705 Tablets

  • Experimental
    High-dose ENERGI-F705 Tablets

    120 milligrams of ENERGI-F705 Tablets

    Drug: 120 milligrams of ENERGI-F705 Tablets

  • Placebo comparator
    Placebo tablets

    Placebo tablets

    Drug: Placebo tablets

Interventions

  • Drug60 milligrams of ENERGI-F705 Tablets

    Tablets will be taken orally twice a day

  • DrugPlacebo tablets

    Tablets will be taken orally twice a day.

  • Drug120 milligrams of ENERGI-F705 Tablets

    Tablets will be taken orally twice a day.

06

What researchers measure

Primary outcomes

  1. Number of participants experiencing adverse events (AE) and serious adverse events (SAE)

    All AEs and SAEs will be assessed following National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version 6.0.

    Time frame: From Day 1 to Week 76

Secondary outcomes

  1. Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III score

    MDS-UPDRS Part III is a scale used by the investigator to evaluate motor functions of Parkinson's disease. The total score ranges from 0 to 132. The higher score indicates more difficulties with movements.

    Time frame: Baseline to Week 72

  2. MDS-UPDRS Part IV score

    MDS-UPDRS Part IV is a scale used by the investigator to evaluate the motor complications in Parkinson's disease. The total score ranges from 0 to 24 with the higher score indicating greater impact on the daily life due to motor complications.

    Time frame: Baseline to Week 72

  3. Sum of MDS-UPDRS Part I score, MDS-UPDRS Part II score and MDS-UPDRS Part III score

    * MDS-UPDRS Part I is a scale, consisting of Part IA (conducted by healthcare professionals) and Part IB (participant's self-assessment), to assess how non-motor symptoms impact daily living. The total score ranges from 0 to 52. The higher score indicates more non-motor symptoms or greater impact on the activities of daily living due to non-motor symptoms. * MDS-UPDRS Part II is a participant's self-assessment to observe how motor symptoms affect your daily living. The total score ranges from 0 to 52. The higher score indicates more motor symptoms or greater impact on the activities of daily living. * MDS-UPDRS Part III is a scale used by the investigator to evaluate motor functions of Parkinson's disease. The total score ranges from 0 to 132. The higher score indicates more difficulties with movements.

    Time frame: Baseline to Week 72

  4. Proportion of participants with 3-point or more increase in MDS-UPDRS Part III score

    MDS-UPDRS Part III is a scale used by the investigator to evaluate motor functions of Parkinson's disease. The total score ranges from 0 to 132. The higher score indicates more difficulties with movements.

    Time frame: Baseline to Week 72

  5. Time to onset of motor complication

    The motor complication events are collected from the MDS-UPDRS Part IV, a scale to evaluate the motor complication in Parkinson's disease. The total score ranges from 0 to 24 with the higher score indicating greater impact on the daily life due to motor complications.

    Time frame: From Day 1 to Week 72

  6. Non-motor symptoms scale (NMSS) total score

    NMSS is a scale to assess non-motor symptoms in Parkinson's disease. It contains 9 subdomains and the total score ranges from 0 to 360. The higher score indicates greater burden of non-motor symptoms.

    Time frame: Baseline to Week 72

  7. Parkinson's Disease Questionnaire-39 (PDQ-39) total score

    PDQ-39 score is to assess the health-related quality of life with Parkinson's disease. The total score is transformed into a percentage score between 0 to 100 with higher percentage indicating worsen health-related quality of life due to Parkinson's disease.

    Time frame: Baseline to Week 72

  8. Modified Hoehn and Yahr stage

    Modified Hoehn and Yahr stage is a scale to evaluate severity of Parkinson's disease in 8 stages. The staging ranges from Stage 0 (No sings of disease) to Stage 5 (Wheelchair bound or bedridden unless aided).

    Time frame: Baseline to Week 72

  9. Levodopa equivalent daily dose (LEDD) of antiparkinsonian medications

    The doses of antiparkinsonian medications will be converted into levodopa equivalent daily dose (LEDD, mg).

    Time frame: Baseline to Week 72

  10. Time to the first LEDD adjustment

    It refers to the changes in LEDD amount (defined as a ≥10% change in LEDD).

    Time frame: From Day 1 to Week 72

  11. Number of participants with abnormalities in vital signs

    Vital signs measurement consist of systolic and diastolic blood pressure, respiratory rate, pulse rate, and body temperature.

    Time frame: Baseline to Week 76

  12. Number of participants with abnormalities in laboratory examination results

    Laboratory examinations consist of the followings: * Hematology: hemoglobin, hematocrit, red blood cell (RBC), platelet, white blood cell (WBC) with differential counts, prothrombin time, international normalized ratio (INR), and activated partial thromboplastin time (APTT) * Biochemistry: total bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), uric acid, blood urea nitrogen (BUN), serum albumin, creatinine, and estimated glomerular filtration rate (eGFR) * Urinalysis: color, appearance, specific gravity, pH, protein, glucose, occult blood, ketones, leukocyte esterase, nitrite, bilirubin, urobilinogen, and microscopic examination of urine sediment

    Time frame: Baseline to Week 76

  13. Number of participants with toxicity grade change for the laboratory examination results

    Toxicity grading will be assessed according to the NCI-CTCAE version 6.0.

    Time frame: Baseline to Week 76

  14. Number of participants with abnormalities in physical examination

    Physical examinations include general appearance, skin, eyes, ears, nose, throat, head and neck (including thyroid), heart, chest and lungs, abdomen, extremities, lymph nodes, musculoskeletal, neurological system, and other body systems if applicable for describing the status of the subject's health.

    Time frame: Baseline to Week 76

  15. Number of participants with transition of electrocardiogram results

    The results of ventricular rate, PR interval, QRS interval, QT interval, RR interval, and QTcB will be recorded.

    Time frame: Baseline to Week 72

Other outcomes

  1. Adenosine triphosphate (ATP) levels in whole blood samples

    The ATP level will be measured using a qualified analytical method at a contracted central laboratory.

    Time frame: Baseline to Week 76

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jan 2030, 37 months later.

Of 97 industry-sponsored phase 2 interventional studies under Parkinson Disease, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 33. This study's planned 37 months is above that.

Counting every sponsor, half of 203 studies reached it within 28 months; a quarter within 16 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2026
First posted
Jun 15, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Jan 1, 2030
CompletionEst.
Jan 1, 2030
Last update
Jul 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07647614
Responsible party
Sponsor
First posted
Jun 15, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Jan 1, 2030 (estimated)
Completion
Jan 1, 2030 (estimated)
Last update
Jul 2, 2026

Study contacts

Yifang Cheng, PhD
Contact
ct@energenesis-biomedical.com
+886-2-26270835
Tu-Hsueh YEH, M.D.
principal investigator · Department of Neurology, Taipei Medical University Hospital
Chien-Tai Hong, M.D.
principal investigator · Department of Neurology, Shuang Ho Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion